| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 112,672 | 112,765 | ||
| Short-term investments | 187,594 | 122,922 | ||
| Prepaid expenses and other current assets | 20,952 | 14,462 | ||
| Total current assets | 321,218 | 250,149 | ||
| Long-term investments | 5,108 | 18,793 | ||
| Right of use assets - operating leases | 49 | 85 | ||
| Other assets | 180 | 479 | ||
| Total assets | 326,555 | 269,506 | ||
| Accounts payable | 5,933 | 4,060 | ||
| Accrued expenses | 15,569 | 15,478 | ||
| Operating lease liabilities | 56 | 98 | ||
| Total current liabilities | 21,558 | 19,636 | ||
| Total liabilities | 21,558 | 19,636 | ||
| Common stock 0.0001 par value, 200,000,000 shares authorized 37,490,439 and 33,706,765 shares issued and outstanding at june 30, 2025 and december 31, 2024, respectively | 4 | 4 | ||
| Additional paid-in capital | 673,884 | 584,003 | ||
| Retained Earnings Accumulated Deficit | - | -334,100 | ||
| Accumulated deficit | -369,097 | -334,119 | ||
| Accumulated other comprehensive income (loss) | 206 | -18 | ||
| Total stockholders' equity | 304,997 | 249,870 | ||
| Total liabilities and stockholders' equity | 326,555 | 269,506 | ||
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)